Leukemia following Hodgkin's disease.

@article{Kaldor1990LeukemiaFH,
  title={Leukemia following Hodgkin's disease.},
  author={J. M. Kaldor and N. E. Day and E Aileen Clarke and Floor E van Leeuwen and Michel Henry-Amar and Mario Vincenzo Fiorentino and Janine Bell and Dorthe Pedersen and Pierre R. Band and David Assouline},
  journal={The New England journal of medicine},
  year={1990},
  volume={322 1},
  pages={
          7-13
        }
}
To investigate the effect of different treatments for Hodgkin's disease on the risk of leukemia, we used an international collaborative group of cancer registries and hospitals to perform a case-control study of 163 cases of leukemia following treatment for Hodgkin's disease. For each case patient with leukemia, three matched controls were chosen who had been treated for Hodgkin's disease but in whom leukemia did not develop. The use of chemotherapy alone to treat Hodgkin's disease was… Expand
Secondary Leukemia following Treatment for Hodgkin's Disease
TLDR
An increased incidence of secondary leukemia occurring in patients treated for Hodgkin's disease is confirmed, and the increased risk seems to be correlated with the number of courses of alkylating agent therapy, whereas it is unaffected by the addition of radiotherapy. Expand
Lung cancer following Hodgkin′s disease: A case‐control study
TLDR
A plausible inference from the study is that all forms of Hodgkin's disease therapy are carcinogenic to the lung and that chemotherapy is associated with an increase in risk which is at least comparable to and perhaps higher than the risk produced by radiotherapy. Expand
Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
TLDR
Since the number of CT episodes was found to be a strong determinant of leukemia risk, it is important that new therapies for HD continue to yield high initial cure rates. Expand
Leukemia Following Chemotherapy for Ovarian Cancer
TLDR
The drugs cyclophosphamide, chlorambucil, melphalan, thiotepa, and treosulfan were independently associated with significantly increased risks of leukemia, as was the combination of doxorubicin hydrochloride and cisplatin. Expand
Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas
TLDR
This study found no significant difference in leukemia risk among lymphoma patients treated with chemotherapy and the combined treatment and found that the overall risk of a second malignancy is no higher after treatment with the combined therapy than with chemotherapy or radiation therapy alone. Expand
Hodgkin's disease: study of treatment intensities and incidences of second malignancies.
TLDR
The analysis suggests that the most critical host factor for developing a second malignancy was age, and the combination of age and stage was the most significant risk factor for AML and non-Hodgkin's lymphoma. Expand
Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
TLDR
Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents, and melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Expand
The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
TLDR
Case-control analysis indicated advanced stage, type and duration of CT and extension of RT as significant risk factors for leukemia, and combined modality therapy with MOPP and extensive RT (including abdomen and pelvis), and the use of lomustine added to the leukemogenic risk of MopP alone were indicated. Expand
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
TLDR
Although the majority of cases have been seen in patients treated with combined-modality therapy, the role of previous therapy in causing this complication cannot be assessed in this study. Expand
Treatment-associated leukemia following testicular cancer.
TLDR
Past treatments for testicular cancer are associated with an increased risk of leukemia, with evidence for dose-response relationships for both radiotherapy and cisplatin-based chemotherapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
TLDR
There appears to be a period of increased risk in patients treated with chemotherapy and radiation, after which the risk of secondary leukemia decreases, and patients surviving for more than 11 years after treatment appear to be at no increased risk of acute leukemia. Expand
Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease.
  • M. Henry-Amar
  • Medicine
  • Journal of the National Cancer Institute
  • 1983
TLDR
The first important risk factor for developing an SC was polychemotherapy, and the second was age over 40 years, which suggest that combination chemotherapy may be responsible for both acute leukemias and other SC. Expand
Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
TLDR
The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives. Expand
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
  • W. Tester, T. Kinsella, +4 authors V. Devita
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1984
TLDR
A positive association was noted between increasing risk of solid tumors and increasing patient age, however, a greater risk of leukemia in patients who began treatment for Hodgkin's disease at age 40 or older was not found. Expand
Second primary cancers following treatment of Hodgkin's disease.
TLDR
A cohort study designed to evaluate the carcinogenicity of treatment for Hodgkin's disease (HD) was conducted and an analysis of follow-up findings through 1978 is presented. Expand
Radiation dose and leukemia risk in patients treated for cancer of the cervix.
TLDR
The model proposed in this study of risk proportional to mass exposed and of risk to an individual given by the sum of incremental risks to anatomic sites appears to be applicable to a wide range of dose distributions. Expand
Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease.
TLDR
Increased lung cancer risk following HD has not frequently been clearly demonstrated before; that it is able to demonstrate such risk may be due to the completeness of follow-up over long periods that could be achieved in this study is demonstrated. Expand
Acute nonlymphocytic leukemia after treatment for Hodgkin's disease.
TLDR
A final decision concerning optimal management of Hodgkin's disease will require definition of the leukemia incidence curve in the second decade after MOPP treatment, and acquisition of additional knowledge of the long-term efficacy and toxicity of alternate treatment regimens. Expand
Risk of second cancers after treatment for Hodgkin's disease.
TLDR
The data suggest that the risk of solid tumors after therapy for Hodgkin's disease continues to increase with time, with the array of neoplasms resembling that previously observed in populations exposed to radiation and in immunosuppressed groups. Expand
Subsequent development of acute non‐lymphocytic leukemia in patients treated for Hodgkin's disease
TLDR
The treatment characteristics associated with an increased risk of developing ANLL were extensive radiotherapy, splenectomy and the chemotherapy combination of vincristine, procarbazine and mechlorethamine. Expand
...
1
2
3
...